Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DENV-4-LVHC Challenge Study
NCT05268302Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of DENV-4-LVHC in dengue fever (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Number of Participants With Solicited Injection Site Adverse Events, Number of Participants With Unsolicited Injection Site Adverse Events and 7 more. Started Feb 2022; status: completed.
02
Drugs
DENV-4-LVHC
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05268302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268302.